AA
IBRX icon

Aire Advisors’s ImmunityBio IBRX Stock Holding History

Aire Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,068
Closed -$49.4K – 166
2025
Q3 		$49.4K Buy
20,068
+3,300
+20% +$8.5K 0.01% 166
2025
Q2 		$44.3K Hold
16,768
– – 0.01% 163
2025
Q1 		$50.5K Buy
16,768
+2,000
+14% +$6.06K 0.01% 153
2024
Q4 		$37.8K Hold
14,768
– – 0.01% 163
2024
Q3 		$54.9K Hold
14,768
– – 0.01% 150
2024
Q2 		$93.3K Buy
14,768
+1
+0% +$7 0.02% 157
2024
Q1 		$79.3K Hold
14,767
– – 0.02% 154
2023
Q4 		$74.1K Sell
14,767
-1
-0% -$3 0.02% 146
2023
Q3 		$25K Buy
+14,768
New +$29.7K 0.01% 139

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Aire Advisors's IBRX Position: Q4 2025 in Review

Aire Advisors sold out of ImmunityBio (IBRX) in Q4 2025, closing a stake of 20,068 shares — an estimated $49.4K sold.

Aire Advisors first reported a position in IBRX in Q3 2023 and held it in 9 quarters. The position peaked at $93.3K in Q2 2024. 278 funds tracked by Wall St. Rank hold IBRX as of Q4 2025.

  • Aire Advisors reported no remaining ImmunityBio position as of Q4 2025 after selling out during the quarter.
  • Aire Advisors sold 20,068 ImmunityBio shares in Q4 2025, an estimated $49.4K.
  • Aire Advisors first reported a position in ImmunityBio in Q3 2023 and held it in 9 quarters.
  • Aire Advisors's ImmunityBio position peaked at $93.3K in Q2 2024.
  • 278 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2025.

Based on Aire Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.